# Ari Shamiss > Ari Shamiss is a Series C investor at Assuta Medical Centers backing Health Care and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Assuta Medical Centers](https://shizune.co/investors/profile/assuta-medical-centers) - Total investments: 3 - Last investment: Mar 2025 - Lead investor: 67% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/ari-shamiss-2515934/ - X (Twitter): https://twitter.com/ishamiss/ - Website: https://x.com/ishamiss/ - Facebook: https://www.facebook.com/ari.shamiss Ari Shamiss is a Series C investor at Assuta Medical Centers focused on Health Care and Medical. Ari Shamiss is the CEO at Assuta Medical Centers. Ari Shamiss attended The Harvard Kennedy School. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 2 | 67% | | Medical | 1 | 33% | | Software | 1 | 33% | | Biopharma | 1 | 33% | | Biotechnology | 1 | 33% | 9 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series C | 2 | 67% | | Series B | 1 | 33% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Navina | Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $55M | Series C | Mar 25, 2025 | | | Navina | Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $22M | Series B | Oct 27, 2022 | | | OncoHost | OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy.Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance.OncoHost was founded in 2017 and is headquartered in Binyamina, Israel. | $35M | Series C | May 10, 2022 | | 3 of 3 investments shown. ## Co-investors - [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 2 deals together - [Vertex Ventures Israel](https://shizune.co/investors/profile/vertex-ventures-israel) — VC Fund, 2 deals together - [Changer Club](https://shizune.co/investors/profile/changer-club) — VC Fund, 1 deal together - [Goldman Sachs Alternatives](https://shizune.co/investors/profile/goldman-sachs-alternatives) — VC Fund, 1 deal together - [Leumi Partners](https://shizune.co/investors/profile/leumi-partners) — VC Fund, 1 deal together - [Menora Mivtachim](https://shizune.co/investors/profile/mivtahim-israels-largest-pension-fund) — VC Fund, 1 deal together ## About Assuta Medical Centers VC Fund 3 contacts available at Assuta Medical Centers. | Name | Title | Profile | | --- | --- | --- | | Ari Shamiss | CEO | https://shizune.co/investors/profile/ari-shamiss | | Dudi Klein | Head of Ventures & Innovation Division | https://shizune.co/investors/profile/dudi-klein | | Yaniv Levinson | Sales Director - Assuta Medical Center, Medical Tourism | https://shizune.co/investors/profile/yaniv-levinson | ## Similar investors ### Similar stage - [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund - [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund ## FAQ ### What does Ari Shamiss invest in? Ari Shamiss invests primarily in Health Care, Medical and Software startups, most often at Series C and Series B stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Ari Shamiss last invest? The most recent investment recorded for Ari Shamiss closed in Mar 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co